TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04947085
Drug: Ketamine via BAN
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine administered via Breath-Actuated Nebulizer (BAN)
Study: NCT04836832
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04836832
Drug: Duvelisib
Normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04869475
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This is a single-arm study with all patients receiving arsenci trioxide.
Study: NCT06348290
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT06348290
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT06348290
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06348290
Drug: dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT06348290
Drug: digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT05224167
Drug: Hydroxyzine
Normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
Study: NCT06096909
Drug: Tafolecimab
Normalized name: Tafolecimab
DrugBank: Tafolecimab (DB16336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.
Study: NCT05208840
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab will be given as slow intravenous infusion. Each treatment cycle has a duration of 6 months (5 cycles are planned in the study). The first cycle will consist of 2 infusions of 300 mg ocrelizumab (second infusion will be performed 14 days after first infusion). Cycles 2 through 5 will consist of one infusion of 600 mg ocrelizumab administered on Day 1 of each cycle.
Study: NCT04998669
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle.
Study: NCT06455046
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1/CTLA-4 bispecific antibody
Study: NCT06455046
Drug: Recombinant Human Adenovirus 5 Injection
Normalized name: Human adenovirus b serotype 7
DrugBank: Human adenovirus b serotype 7 (DB14410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Adenovirus 5 Injection
Study: NCT05657873
Drug: Platinum based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
Study: NCT01076439
Drug: Fluticasone Furoate Nasal Spray
Normalized name: fluticasone furoate Metered Dose Nasal Spray
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate Nasal Spray: 110mcg QD
Study: NCT01076439
Drug: Olopatadine Nasal Spray
Normalized name: olopatadine Metered Dose Nasal Spray
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine Nasal Spray: 2660mcg BID
Study: NCT04448028
Drug: Esomeprazole 20mg
Normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
Study: NCT04998669
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.
Study: NCT06193044
Drug: Amlodipine/Valsartan
Normalized name: AMLODIPINE/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Amlodipine 10 mg \&valsartan 160 mg
Study: NCT06193044
Drug: Amlodipine 10 mg &valsartan 160 mg (Exforge)
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Amlodipine 10 mg \&valsartan 160 mg
Study: NCT06357676
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06145399
Drug: 18F-FDHT
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
Study: NCT05751018
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
Study: NCT04660097
Drug: Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.
Study: NCT06319950
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib, 160mg po qd
Study: NCT06319950
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib，80mg po qd
Study: NCT04764669
Drug: E2027
Normalized name: Elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hypromellose capsules.
Study: NCT04667793
Drug: Toripalimab + Chemotherapy
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel
Study: NCT05519540
Drug: Xevinapant (Debio 1143)
Normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants (Japanese and non-Japanese East Asian) will receive single oral dose of xevinapant (Debio 1143) on Day 1.
Study: NCT05450900
Drug: Choriogonadotropin Alpha
Normalized name: choriogonadotropin alpha
DrugBank: Choriogonadotropin alfa (DB00097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug, active
Study: NCT04726969
Drug: Moxidectin 2 mg Oral Tablet
Normalized name: moxidectin 2 mg ORAL TABLET
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets of 2 mg moxidectin
Study: NCT04726969
Drug: Albendazole 400 mg Oral Tablet
Normalized name: albendazole 400 MG Oral Tablet
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets of 400 mg albendazole
Study: NCT04726969
Drug: Ivermectin 3 mg Oral Tablet
Normalized name: ivermectin 3 MG Oral Tablet
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets of 3 mg ivermectin
Study: NCT05037799
Drug: Rb-82 Radioisotope
Normalized name: Rubidium Rb-82
DrugBank: Rubidium Rb-82 (DB09479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight
Study: NCT02614352
Drug: Atorvastatin + Candesartan
Normalized name: atorvastatin, amlodipine and candesartan
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05182840
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets
Study: NCT05182840
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin
Study: NCT05182840
Drug: Placebo to empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo to empagliflozin
Study: NCT05742607
Drug: IPH5201 + durvalumab + standard chemotherapy
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.
Study: NCT05366868
Drug: Imeglimin
Normalized name: imeglimin
DrugBank: Imeglimin (DB12509)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
Study: NCT05366868
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
Study: NCT05366868
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
Study: NCT06355180
Drug: Subanesthetic dose intravenous esketamine
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study, lasting 12 weeks, includes a 2-week intervention and 10-week follow-up. Esketamine (0.2mg/kg) is given intravenously three times a week for two weeks. Dosage and sessions may adjust for safety and efficacy, with study treatments limited during follow-up.~Efficacy is evaluated via scales measuring suicidal ideation, depression, cognition, and social function. Adverse effects are tracked through vital signs, exams, events, and tests.~Biological samples (blood, urine, feces) are collected from some participants at baseline, post-first, and sixth treatments for omics analyses.~Brain imaging from some participants at baseline and post-sixth treatment aims to obtain high-resolution T1, T2 FLAIR, resting fMRI, and DTI images.~Electrophysiological data, including resting state EEG signals and task paradigms, are collected from some participants at baseline, after the first, and sixth treatments.
Study: NCT04928625
Drug: SHR-A1904
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1904
Study: NCT05214339
Drug: Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
Study: NCT05805072
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor 60 mg/day, orally on d1,4,8,11
Study: NCT05805072
Drug: Homoharringtonine
Normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homoharringtonine 1 mg/day intravenously on days 3 to 9
Study: NCT05805072
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9
Study: NCT05805072
Drug: Aclacinomycin
Normalized name: Aclacinomycin
DrugBank: Aklavine (DB19070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aclacinomycin 10 mg/day intravenously on days 3 to 6
Study: NCT05805072
Drug: Granulocyte Colony-Stimulating Factor
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,
Study: NCT05805072
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m2/day intravenously on days 1 to 5.
Study: NCT05805072
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7
Study: NCT05358704
Drug: combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
Study: NCT04527900
Drug: carboplatin and paclitaxel
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin and paclitaxel 5-6 cycles (dosage per standard of care according to treating oncologist)
Study: NCT04708236
Drug: ORTD-1 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.
Study: NCT04708236
Drug: ORTD-1 high dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.
Study: NCT04744090
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1. Roflumilast 500 mcg daily for up to 28 days~2. Total follow up time will be 28 days.~3. Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~4. Roflumilast will be combined with standard of care for ARDS.~5. During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~6. During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~7. In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended.
Study: NCT05796206
Drug: MIL62
Normalized name: Milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
Study: NCT04684238
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution for Injection/Infusion
Study: NCT04684238
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
Study: NCT04901689
Drug: Leronlimab
Normalized name: Leronlimab
DrugBank: Leronlimab (DB05941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leronlimab 700 mg
Study: NCT06287177
Drug: Inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Injection
Study: NCT06326723
Drug: Daridorexant
Normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.).
Study: NCT05816499
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV, 10mg/kg Q3W
Study: NCT05816499
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral，6mg/8mg/10mg qd 2W/3W
Study: NCT05816499
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV, 60-75mg/m2 Q3W
Study: NCT05439005
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine+Lidocaine
Study: NCT06571383
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive semaglutide s.c(under the skin) once weekly.
Study: NCT05423262
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg administered intravenously over 30 minutes (bi-weekly)
Study: NCT05610280
Drug: Olezarsen
Normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen will be administered by SC injection.
Study: NCT05040113
Drug: CBP-307
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBP-307 capsules oral administration
Study: NCT04909918
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol.Intravenous dexamethasone 8 mg/day given for 7 days
Study: NCT06607263
Drug: Mouthwash CPC+Zn+F
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mouthwash containing CPC + Zn and fluoride
Study: NCT06607263
Drug: Essential oils mouthrinse
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oils mouthrinse
Study: NCT04909918
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol. Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
Study: NCT00002069
Drug: Ditiocarb sodium
Normalized name: Ditiocarb zinc
DrugBank: Ditiocarb (DB02520)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06254131
Drug: Ondansetron lozenge (Ondalenz ©)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
Study: NCT06254131
Drug: Ondansetron IV
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
Study: NCT05960721
Drug: Rivaroxaban 15mg
Normalized name: RIVAROXABAN 15MG TAB
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: QD
Study: NCT05960721
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QD
Study: NCT05960721
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: QD
Study: NCT05960721
Drug: Rivaroxaban 10mg
Normalized name: RIVAROXABAN 10MG TAB
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: QD
Study: NCT05960721
Drug: Rivaroxaban 2.5mg
Normalized name: RIVAROXABAN 2.5MG TAB
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: B.I.D
Study: NCT04211675
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is \<0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.